• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Facebook
  • Instagram
  • LinkedIn
  • TikTok
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact
  • English
  • Spanish

European Commission authorises first safe and effective vaccine against COVID-19

Inicio » EU News » Health » Diseases » European Commission authorises first safe and effective vaccine against COVID-19

22 de December de 2020

The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by BioNTech and Pfizer, making it the first COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.

European Commission authorises first safe and effective vaccine against COVID-19

The President of the European Commission, Ursula von der Leyen, said: “Today we add an important chapter to a European success story. We approved the first safe and effective vaccine against COVID-19. More vaccines will come soon. Doses of the vaccine approved today will be available for all EU countries, at the same time, on the same conditions. The upcoming European vaccination days will also be a great moment of unity. This is a good way to end this difficult year, and to start turning the page on this pandemic. We are all in this together.”

EMA’s human medicines committee has completed its rigorous evaluation of Comirnaty, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available to recommend a formal conditional marketing authorisation. This will provide a controlled and robust framework to underpin EU-wide vaccination campaigns and protect EU citizens.

“Today’s positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for so many,” said Emer Cooke, Executive Director of EMA. “We have achieved this milestone thanks to the dedication of scientists, doctors, developers and trial volunteers as well as many experts from all EU Member States.

“Our thorough evaluation means that we can confidently assure EU citizens of the safety and efficacy of this vaccine and that it meets necessary quality standards. However, our work does not stop here. We will continue to collect and analyse data on the safety and effectiveness of this vaccine to protect people taking the vaccine in the EU.”

Efficacy was calculated in over 36,000 people from 16 years of age (including people over 75 years of age) who had no sign of previous infection. The study showed a 95% reduction in the number of symptomatic COVID-19 cases in the people who received the vaccine (8 cases out of 18,198 got COVID-19 symptoms) compared with people who received a dummy injection (162 cases out of 18,325 got COVID-19 symptoms). This means that the vaccine demonstrated a 95% efficacy in the clinical trial.

Comirnaty is given as two injections into the arm, at least 21 days apart. The most common side effects with Comirnaty were usually mild or moderate and got better within a few days after vaccination. They included pain and swelling at the injection site, tiredness, headache, muscle and joint pain, chills and fever. The safety and effectiveness of the vaccine will continue to be monitored as it is used across the Member States, through the EU pharmacovigilance system and additional studies by the company and by European authorities.

More information

European Commission

Eurpoean Medicines Agency

Publicaciones relacionadas:

EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen European Commission authorises second safe and effective vaccine against COVID-19 EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca First COVID-19 vaccine approved for children aged 12 to 15 in EU Waging war against SARS-CoV-2 with Europe’s most powerful supercomputers

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas


EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen


European Commission authorises second safe and effective vaccine against COVID-19


EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca


First COVID-19 vaccine approved for children aged 12 to 15 in EU


Waging war against SARS-CoV-2 with Europe’s most powerful supercomputers

Footer

Logotipo en negativo del Centro de Documentación Europea de Almería
  • CDE Almería
  • Edificio Parque Científico-Tecnológico (Pita)
  • Planta: 1ª, Despacho: 2904120.
  • Ctra. Sacramento s/n. Almería (Spain)
  • Teléfono: (+34) 950 015266

HOME
NEWS
DOCUMENTATION
EUROPE ON THE NET
ABOUT US

  • LEGAL NOTICE
  • PRIVACY POLICY
  • COOKIE POLICY
  • ACCESSIBILITY
  • SITEMAP

Copyright © 2023 CDE Almería · Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

<p>El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. ajustes</p>

Politica de privacidad

El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. <a href="/politica-de-cookies" rel="noopener" target="_blank">Más información</a>

Cookies estrictamente necesarias

Las cookies estrictamente necesarias tiene que activarse siempre para que podamos guardar tus preferencias de ajustes de cookies.

Básicamente la web no funcionara bien si no las activas.

Estas cookies son:

  • Comprobación de inicio de sesión.
  • Cookies de seguridad.
  • Aceptación/rechazo previo de cookies.

Si desactivas esta cookie no podremos guardar tus preferencias. Esto significa que cada vez que visites esta web tendrás que activar o desactivar las cookies de nuevo.

Cookies de terceros

Esta web utiliza Google Analytics, Google Tag Manager y Yandex Metrika para recopilar información anónima tal como el número de visitantes del sitio, o las páginas más populares.

Dejar estas cookies activas nos permite mejorar nuestra web.

¡Por favor, activa primero las cookies estrictamente necesarias para que podamos guardar tus preferencias!

Política de cookies

Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. Más información